Amgen (NSDQ:AMGN) announced today that it completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX).
Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021.
Get the full story at our sister site, Drug Delivery Business News.